Taming U.S. healthcare spending is a huge, daunting task that has met with little success. But some Yale professors are proposing to take a bite-sized approach as a way to change that.
Taming U.S. healthcare spending is a huge, daunting task that has met with little success. But some Yale professors are proposing to take a bite-sized approach as a way to change that.
The “1% Steps for Health Care Reform” project launched by Zach Cooper, Ph.D., and Fiona Scott Morton, Ph.D., promises to offer up “a menu of tangible steps that policymakers can take to lower healthcare costs in the U.S.”
To that end, the project’s website currently has 16 policy briefs posted. Each carries an estimate of the percentage by which proposals in the briefs could reduce healthcare spending.
For example, Cooper and Morton estimate that the changes they propose in their policy brief on out-of-network billing by hospital-based physicians could save$60 billion annually, or 5% of commercial healthcare spending. By their calculation, that works out to 1.67% of total U.S. healthcare spending.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Accepts Tabelecleucel BLA; Priority Review Granted for Post-Transplant Disease Therapy
July 24th 2025The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Read More